Sol-Gel Technologies vs Zentalis Pharmaceuticals
SLGL and ZNTL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SLGL and ZNTL compare
Sol-Gel Technologies scores higher on the StockData Score (10 against 6 for Zentalis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SLGL | ZNTL |
|---|---|---|
| Size and price | ||
| Market cap | – | $122M |
| Share price | $55.12 | $1.70 |
| Change, 1 year | 75.0% | 26.9% |
| Change, 5 years | −35.7% | −97.8% |
| Beta (5Y) | 1.00 | 2.14 |
| Employees | 28 | 106 |
| StockData Score | ||
| Total score | 10 (better) | 6 |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 3 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 0.6× |
| FCF yield | – | −110% |
| Growth | ||
| Revenue growth (TTM) | 68.0% | – |
| Revenue growth, 5Y average | 17.2% | – |
| Profitability | ||
| Operating margin | −38.9% | – |
| Net margin | −31.6% | – |
| FCF margin | 1.4% | – |
| Return on equity | −15.3% (better) | −61.9% |
| Return on invested capital | −153% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 10.37 (better) | 7.33 |
| Altman Z-score | – | −6.54 |
| Piotroski F-score | 5 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 47.5% | 66.1% |
| Held by insiders | 70.2% | 58.0% |
| Insider net buying, 12 months | $11.0M | $12.8M (better) |
| Short interest, % of float | 16.3% | 16.7% |
Go deeper
- SLGL stock overview
- SLGL income statement
- SLGL valuation and score
- ZNTL stock overview
- ZNTL income statement
- ZNTL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.